Ann: Initial Oraline Product Run Completed , page-21

Hi Harvett

whilst that may be the case in the past the company now has:
- cash of $1.3m (at 31 March 2014)
- cash at 30/9/2013 was $1.6m, so a pretty low cash burn over 6 months
- a totally different board (the guys behind ASX companies OSL and CYP)
- an "improved" Oraline. I assume this means they have at least considered the competitors products and fixed any previous problems with Oraline
- manufacturing partnerships in place (Beichi & Lumiquick)
- outsourced development using experts (Beichi)
- extensive trademark coverage
- Oraline testing complete, distribution channels in place
- various other ideas for their IP, such as genomic/genetic testing, electronic handheld testing (mentioned in recent announcements), asthma / airway inflammation
- the board have said they are looking at other opportunities in therapeutics
- the board's salaries are very modest ($5k per month I think)

They are probably better placed than they have ever been to generate revenue from Oraline, but IMO SBN is not just about Oraline.

The history of SBN may be bad, but the history of current management is not.